Does the Cyclosporine Still Have a Potential Role in the Treatment of Acute Severe Steroid-Refractory Ulcerative Colitis?

참고문헌 (9)

1. 박성철, "Current and Emerging Biologics for Ulcerative Colitis", Gut and Liver, 9(1), pp.18~27 (2015), 거트앤리버 발행위원회
2. 서현일, "The Effect of Infliximab on Patients with Ulcerative Colitis in Korea", Intestinal research, 12(3), pp.214~220 (2014), 대한장연구학회
3. Sjöberg M, "Infliximab or cyclosporine as rescue therapy in hospitalized patients with steroid-refractory ulcerative colitis: a retrospective observational study", Inflamm Bowel Dis, 18, pp.212~218 (2012)
4. Croft A, "Outcomes of salvage therapy for steroid-refractory acute severe ulcerative colitis: ciclosporin vs. infliximab", Aliment Pharmacol Ther, 38, pp.294~302 (2013)
5. Chang KH, "Infliximab versus cyclosporine as rescue therapy in acute severe steroid-refractory ulcerative colitis: a systematic review and meta-analysis", Int J Colorectal Dis, 28, pp.287~293 (2013)
6. Laharie D, "Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial", Lancet, 380, pp.1909~1915 (2012)
7. 한동수, "Current Status and Prospects of Intestinal Microbiome Studies", Intestinal research, 12(3), pp.178~183 (2014), 대한장연구학회
8. 정윤숙, "Seasonal Variation in Months of Birth and Symptom Flares in Korean Patients with Inflammatory Bowel Disease", Gut and Liver, 7(6), pp.661~667 (2013), 거트앤리버 발행위원회
9. 김은혜, "Infliximab versus Cyclosporine Treatment for Severe Corticosteroid-Refractory Ulcerative Colitis: A Korean, Retrospective, Single Center Study", Gut and Liver, 9(5), pp.601~606 (2015), 거트앤리버 발행위원회